Strumento inattivo

Azioni Pharmacyclics, Inc.

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	07/01/16
Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	07/01/16
Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	07/01/16
Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	07/01/16
Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	07/01/16

Dirigenti	Titolo	Età	Da
Wulff-Erik von Borcke CEO	Chief Executive Officer	-	01/05/15
Betty Chang CTO	Chief Tech/Sci/R&D Officer	-	09/07/13
Heow Tan CTO	Chief Tech/Sci/R&D Officer	65	01/05/12

Settore

	Variaz. 1 gen.	Capi.
IQVIA HOLDINGS INC.	+1,51%	42,75 Mrd
LONZA GROUP AG	+49,22%	41,61 Mrd
MODERNA, INC.	+8,57%	41,34 Mrd
CELLTRION, INC.	-12,36%	26,59 Mrd
ICON PUBLIC LIMITED COMPANY	+8,92%	25,49 Mrd
ALNYLAM PHARMACEUTICALS, INC.	-25,13%	18,12 Mrd
MEDPACE HOLDINGS, INC.	+29,17%	12,24 Mrd
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3,12%	11,76 Mrd
UNITED THERAPEUTICS CORPORATION	+6,35%	11 Mrd